Plasma and CSF neurofilament light chain distinguish neurodegenerative from primary psychiatric conditions in a clinical setting
Alzheimer's & Dementia · 2024-11 · 20 (11) · 7989-8001
DOI: 10.1002/alz.14278 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 06.10.2024. Verfasst von Dhamidhu Eratne und 30 weiteren Autor:innen. Beteiligte Einrichtung: Neuropsychiatry Centre, The Royal Melbourne Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Neurofilament Proteins, Neurodegenerative Diseases, Biomarkers, Mental Disorders. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, European Union's Horizon Europe research and innovation programme, Swedish State Support for Clinical Research.
Abstract (Originalsprache)
INTRODUCTION People with neurodegenerative disorders (ND) frequently face diagnostic delay and misdiagnosis. We investigated blood and cerebrospinal fluid (CSF) neurofilament light chain (NfL) to distinguish ND from primary psychiatric disorders (PPD), a common challenge in clinical settings. METHODS Plasma and CSF NfL levels were measured and compared between groups, adjusting for age, sex, and weight. RESULTS A total of 337 participants were included: 136 ND, 77 PPD, and 124 Controls. Plasma NfL was 2.5‐fold elevated in ND compared to PPD and had strong diagnostic performance (area under the curve, [AUC]: 0.86, 81%/85% specificity/sensitivity) that was comparable to CSF NfL (2‐fold elevated, AUC: 0.89, 95%/71% specificity/sensitivity). Diagnostic performance was especially strong in younger people (40– < 60 years). Additional findings were cutoffs optimized for sensitivity and specificity, and issues important for future clinical translation. CONCLUSIONS This study adds important evidence for a simple blood‐based biomarker to assist as a screening test for neurodegeneration and distinction from PPD, in clinical settings. Highlights NfL levels were significantly higher in ND versus PPD. Plasma NfL showed strong diagnostic performance, comparable to CSF NfL, to distinguish ND from PPD. Diagnostic performance was higher in younger people, where diagnostic challenges are greater. Further research is needed on analytical and reference range factors, for clinical translation. These findings support a simple screening blood test for neurodegeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuropsychiatry Centre, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Department of Psychiatry, The University of Melbourne, Melbourne, Victoria, Australia.
- The Florey, Melbourne, Victoria, Australia.
- Institute of Health and Wellbeing, Federation University, Melbourne, Victoria, Australia.
- National Ageing Research Institute, Melbourne, Victoria, Australia.
- Department of General Practice, The University of Melbourne, Melbourne, Victoria, Australia.
ORCID-Profile: Dhamidhu Eratne
Förderung
- Swedish Research Council
- European Union's Horizon Europe research and innovation programme
- Swedish State Support for Clinical Research
- Department of Psychiatry
- University of Melbourne
- Ramsay Hospital Research Foundation
- Australian Commonwealth Government
- NHMRC
Zitieren
APA
Eratne, D., Kang, M. J. Y., Lewis, C., Dang, C., Malpas, C. B., Keem, M., Grewal, J., Marinov, V., Coe, A., Kaylor-Hughes, C., Borchard, T., Keng-Hong, C., Waxmann, A., Saglam, B., Kalincik, T., Kanaan, R., Kelso, W., Evans, A., Farrand, S., …, & MiND Study Group (2024). Plasma and CSF neurofilament light chain distinguish neurodegenerative from primary psychiatric conditions in a clinical setting. Alzheimer's & Dementia, 20(11), 7989-8001. https://doi.org/10.1002/alz.14278
Vancouver
Eratne D, Kang MJY, Lewis C, Dang C, Malpas CB, Keem M, et al. Plasma and CSF neurofilament light chain distinguish neurodegenerative from primary psychiatric conditions in a clinical setting. Alzheimer's & Dementia. 2024;20(11):7989-8001. doi:10.1002/alz.14278
BibTeX
@article{Eratne2024,
author = {Eratne, Dhamidhu and Kang, Matthew J Y and Lewis, Courtney and Dang, Christa and Malpas, Charles B and Keem, Michael and Grewal, Jasleen and Marinov, Vladimir and Coe, Amy and Kaylor-Hughes, Cath and Borchard, Thomas and Keng-Hong, Chhoa and Waxmann, Alexandra and Saglam, Burcu and Kalincik, Tomas and Kanaan, Richard and Kelso, Wendy and Evans, Andrew and Farrand, Sarah and Loi, Samantha and Walterfang, Mark and Stehmann, Christiane and Li, Qiao-Xin and Collins, Steven and Masters, Colin L and Santillo, Alexander F and Zetterberg, Henrik and Blennow, Kaj and Berkovic, Samuel F and Velakoulis, Dennis and MiND Study Group, MiND Study Group},
title = {Plasma and CSF neurofilament light chain distinguish neurodegenerative from primary psychiatric conditions in a clinical setting},
journal = {Alzheimer's & Dementia},
year = {2024},
volume = {20},
number = {11},
pages = {7989--8001},
doi = {10.1002/alz.14278}
}
EUVIMED